Related Experiment Videos
Frequent inactivation of the transforming growth factor beta type II receptor in small-cell lung carcinoma cells
R R de Jonge1, L Garrigue-Antar, V F Vellucci
1Department of Medicine, Yale University School of Medicine, New Haven, CT 06520-8032, USA.
Abstract:
Small-cell lung cancer (SCLC) has a significantly worse prognosis than other forms of bronchogenic carcinoma. Because transforming growth factor beta (TGF-beta) appears to play an important role in the pathogenesis of SCLC, we examined the status of the TGF-beta receptor system in a series of 11 human small-cell carcinoma cell lines. None of these cell lines expressed more than one-tenth the level of TGF-beta type II receptor (T beta R-II) gene mRNA produced by TGF-beta-sensitive normal epithelial cells. In addition, one of the cell lines expressed a second truncated T beta R-II transcript, which is predicted to encode a protein that lacks the terminal two-thirds of the serine-threonine kinase domain. No other structural alterations in the promoter or coding sequences of the T beta R-II gene were found in any of the cell lines, nor could the loss of T beta R-II mRNA expression be ascribed to de novo hypermethylation of promoter/enhancer sequences. These findings indicate that inactivation of the TGF-beta signaling pathway caused by the loss of T beta R-II gene expression is a common and, therefore, probably pathogenetically important feature of small-cell lung carcinoma.
Insights
Small-cell lung cancer cells frequently lose expression of the TGF-beta type II receptor (T beta R-II). This inactivation of the TGF-beta signaling pathway is common and likely contributes to the poor prognosis of SCLC.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Small-cell lung cancer (SCLC) exhibits a poorer prognosis compared to other lung cancers.
- Transforming growth factor beta (TGF-beta) signaling is implicated in SCLC pathogenesis.
Purpose of the Study:
- To investigate the status of the TGF-beta receptor system in human SCLC cell lines.
- To determine the role of TGF-beta receptor expression in SCLC development.
Main Methods:
- Analysis of TGF-beta type II receptor (T beta R-II) gene mRNA expression in 11 SCLC cell lines.
- Investigation of T beta R-II gene structural alterations, including promoter and coding sequences.
- Assessment of T beta R-II mRNA expression levels relative to normal epithelial cells.
Main Results:
- All examined SCLC cell lines showed significantly reduced T beta R-II mRNA expression (less than 10% of normal levels).
- One cell line displayed a truncated T beta R-II transcript, potentially encoding a non-functional protein.
- No structural gene alterations or promoter hypermethylation were identified as the cause for reduced expression.
Conclusions:
- Loss of T beta R-II gene expression is a frequent characteristic of SCLC.
- Inactivation of the TGF-beta signaling pathway due to diminished T beta R-II expression is likely a key factor in SCLC pathogenesis.